MD20190080A2 - Forme cristaline de (s)-afoxolaner - Google Patents

Forme cristaline de (s)-afoxolaner Download PDF

Info

Publication number
MD20190080A2
MD20190080A2 MDA20190080A MD20190080A MD20190080A2 MD 20190080 A2 MD20190080 A2 MD 20190080A2 MD A20190080 A MDA20190080 A MD A20190080A MD 20190080 A MD20190080 A MD 20190080A MD 20190080 A2 MD20190080 A2 MD 20190080A2
Authority
MD
Moldova
Prior art keywords
crystalline forms
afoxolaner
animals
prevention
compositions
Prior art date
Application number
MDA20190080A
Other languages
English (en)
Russian (ru)
Inventor
ДЕ ВРИС Рулоф Йоханнес ГОРТЕР
Брюно БАЙОН
Силвайн ЛАФОН
ДЕ СЕН МИШЕЛЬ Мириам ГЕЙ
Стефан КОЗЛОВИЦ
Original Assignee
Boehringer Ingelheim Animal Health USA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Animal Health USA Inc. filed Critical Boehringer Ingelheim Animal Health USA Inc.
Publication of MD20190080A2 publication Critical patent/MD20190080A2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Secondary Cells (AREA)

Abstract

Prezenta invenţie se referă la forme cristaline ale compusului cu formula (Ia) şi procedee de obţinere a formelor cristaline, precum şi la compoziţii, care conţin forme cristaline, şi forme cristaline pentru tratarea sau profilaxia infecţiilor parazitare la animale.(Ia)
MDA20190080A 2017-04-05 2018-04-05 Forme cristaline de (s)-afoxolaner MD20190080A2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482175P 2017-04-05 2017-04-05
PCT/US2018/026328 WO2018187623A1 (en) 2017-04-05 2018-04-05 Crystalline forms of (s)-afoxolaner

Publications (1)

Publication Number Publication Date
MD20190080A2 true MD20190080A2 (ro) 2020-04-30

Family

ID=62092252

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20190080A MD20190080A2 (ro) 2017-04-05 2018-04-05 Forme cristaline de (s)-afoxolaner

Country Status (22)

Country Link
US (2) US10662163B2 (ro)
EP (1) EP3606911A1 (ro)
JP (1) JP7222909B2 (ro)
KR (1) KR102612648B1 (ro)
CN (2) CN111032634B (ro)
AR (1) AR111412A1 (ro)
AU (1) AU2018250304B2 (ro)
CA (1) CA3059114A1 (ro)
CL (1) CL2019002840A1 (ro)
CO (1) CO2019011980A2 (ro)
EA (1) EA201992360A1 (ro)
IL (1) IL269792B (ro)
MD (1) MD20190080A2 (ro)
MX (1) MX2019011931A (ro)
MY (1) MY188420A (ro)
PH (1) PH12019502277A1 (ro)
SG (1) SG11201909229SA (ro)
TW (1) TWI782976B (ro)
UA (1) UA125727C2 (ro)
UY (2) UY37665A (ro)
WO (1) WO2018187623A1 (ro)
ZA (1) ZA201906464B (ro)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner
WO2021254445A1 (zh) * 2020-06-19 2021-12-23 东莞市东阳光仿制药研发有限公司 一种gaba抑制剂的晶型及其制备方法
KR20230043904A (ko) 2020-07-24 2023-03-31 엘랑코 유에스 인코포레이티드 이속사졸린 화합물 및 이의 중간체의 제조 공정
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
CN117486869A (zh) * 2023-11-06 2024-02-02 北京康立生医药技术开发有限公司 一种眼科治疗药物新的制备方法
CN118536571B (zh) * 2024-05-31 2025-02-25 北京无问芯穹科技有限公司 一种构建扩散变换器模型的方法、系统、设备及存储介质
WO2025257633A1 (en) 2024-06-12 2025-12-18 Boehringer Ingelheim Vetmedica Gmbh Long-acting castor oil-containing injectable formulations and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI649303B (zh) * 2007-08-17 2019-02-01 杜邦股份有限公司 製備４-乙醯基-ｎ-〔２-側氧基-２-〔（２，２，２-三氟乙基）胺基〕乙基〕-１-萘甲醯胺之化合物及方法
EP2576523B1 (en) 2010-05-27 2016-01-13 E. I. du Pont de Nemours and Company Crystalline form of 4-[5 - [3 -chloro-5 -(trifluoromethyl)phenyl] -4,5 -dihydro-5 -(trifluoromethyl)-3 - isoxazolyl]-n-[2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl]-1- naphthalenecarboxamide
RS61048B1 (sr) * 2011-09-12 2020-12-31 Boehringer Ingelheim Animal Health Usa Inc Paraziticidne kompozicije koje sadrže izoksazolin aktivni agens, postupak i njihove primene
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP2015028006A (ja) * 2013-06-27 2015-02-12 日産化学工業株式会社 イソキサゾリン化合物の結晶性多形体およびその製造方法
PY1609250A (es) * 2015-02-26 2018-03-01 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG11201708068PA (en) * 2015-04-08 2017-10-30 Merial Inc Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
MX378893B (es) 2016-04-06 2025-03-11 Boehringer Ingelheim Vetmedica Gmbh Proceso para preparar compuestos de isoxazolina.
CA3059114A1 (en) * 2017-04-05 2018-10-11 Boehringer Ingelheim Animal Health USA Inc. Crystalline forms of (s)-afoxolaner

Also Published As

Publication number Publication date
UA125727C2 (uk) 2022-05-25
UY37665A (es) 2018-10-31
WO2018187623A8 (en) 2019-10-24
MX2019011931A (es) 2020-01-13
SG11201909229SA (en) 2019-11-28
AU2018250304A1 (en) 2019-10-31
JP2020513010A (ja) 2020-04-30
CO2019011980A2 (es) 2020-02-18
BR112019021072A2 (pt) 2020-05-12
UY40794A (es) 2024-07-15
MY188420A (en) 2021-12-08
CN111032634A (zh) 2020-04-17
NZ757869A (en) 2024-11-29
KR20190136055A (ko) 2019-12-09
CL2019002840A1 (es) 2020-01-10
AR111412A1 (es) 2019-07-10
TWI782976B (zh) 2022-11-11
TW201841895A (zh) 2018-12-01
IL269792B (en) 2022-04-01
AU2018250304B2 (en) 2022-03-03
EA201992360A1 (ru) 2020-09-02
US20200270219A1 (en) 2020-08-27
US20180354917A1 (en) 2018-12-13
CA3059114A1 (en) 2018-10-11
CN111032634B (zh) 2025-04-11
KR102612648B1 (ko) 2023-12-11
WO2018187623A1 (en) 2018-10-11
ZA201906464B (en) 2021-08-25
JP7222909B2 (ja) 2023-02-15
US11130739B2 (en) 2021-09-28
EP3606911A1 (en) 2020-02-12
CN120172925A (zh) 2025-06-20
IL269792A (en) 2019-11-28
US10662163B2 (en) 2020-05-26
PH12019502277A1 (en) 2020-09-14

Similar Documents

Publication Publication Date Title
MD20190080A2 (ro) Forme cristaline de (s)-afoxolaner
EA201791011A1 (ru) 3-ЗАМЕЩЕННЫЕ 5-АМИНО-6H-ТИАЗОЛО[4,5-d]ПИРИМИДИН-2,7-ДИОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИРУСНЫХ ИНФЕКЦИЙ
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201800367A1 (ru) Способы лечения болезни хантингтона
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
EA201691766A1 (ru) Органические соединения, являющиеся монобактамами, для лечения бактериальных инфекций
EA201690844A1 (ru) Ингибиторы gsk-3
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201792021A1 (ru) Ингибитор jak
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
EA201790337A1 (ru) Кристаллические формы ингибиторов глутаминазы
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201791353A1 (ru) СОЕДИНЕНИЯ ИЗОКСАЗОЛГИДРОКСАМИНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ LpxC
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа

Legal Events

Date Code Title Description
GB9A Change of applicant (patent for invention)

Owner name: BOEHRINGER INGELHEIM VETMEDICA GMBH, DEBINGER STRASSE 173, 55216 INGELHEIM AM RHEIN, GERMANIA

Free format text: PREVIOUS APPLICANT: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC., US3239 SATELLITE BLVD. DULUTH, GA 30096, STATELE UNITE ALE AMERICII